Concepedia

Author

Saengsuree Jootar

Ramathibodi Hospital

Also Known As

Dongho Kim, S Jootar, S. JOOTAR, S. Jootar, Saengsuree Jootar, Sukjoong Oh, Tomasz Szczudlo

124

Publications

2.2K

Citations

24

H-Index

69

Concepts

All Affiliations

Ramathibodi HospitalMahidol UniversityCatholic University of KoreaThe Catholic University of Korea Seoul St. Mary's HospitalNovartis (Switzerland)
SJ

About

Saengsuree Jootar is an author at Ramathibodi Hospital specializing in medicine, hematology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

22

640

2

Health Sciences

7

7

176

3

Public Health

2

2

44

4

Engineering

1

1

23

5

Biomedical Engineering

1

1

23

Saengsuree Jootar

×

45

Publications

1.9K

Citations

24

H-Index

YearCitations

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

Hagop Kantarjian, Ricardo Pasqüini, Nelson Hamerschlak,

Blood

2007

377

Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

Hagop M. Kantarjian, Ricardo Pasqüini, Vincent Lévy,

Cancer

2009

211

Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies

Kearkiat Praditpornsilpa, Khajohn Tiranathanagul, Pawinee Kupatawintu,

Kidney International

2011

106

Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Jae-Yong Kwak, Sung‐Hyun Kim, Suk Joong Oh,

Clinical Cancer Research

2017

74

Expanding Nilotinib Access in Clinical Trials (ENACT)

Franck E. Nicolini, Anna Turkina, Zhixiang Shen,

Cancer

2011

68

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

S.-H. Kim, Hari Menon, Saengsuree Jootar,

Haematologica

2014

67

Outcomes of Transplantation with Related- and Unrelated-Donor Stem Cells in Children with Severe Thalassemia

Suradej Hongeng, Samart Pakakasama, Ampaiwan Chuansumrit,

Biology of Blood and Marrow Transplantation

2006

58

Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases

Tanin Intragumtornchai, Wichai Prayoonwiwat, Daratana Swasdikul,

Leukemia Research

1998

48

Generation of CD3+CD56+ Cytokine-Induced Killer Cells and Their In Vitro Cytotoxicity against Pediatric Cancer Cells

Suradej Hongeng, Sawang Pctviscs, Surapon Worapongpaiboon,

International Journal of Hematology

2003

48

ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes

Giuseppe Saglio, Andreas Hochhaus, Timothy P. Hughes,

Blood

2013

47

Page 1